Publications by authors named "Y-C Ghim"
Clin Transl Sci
July 2021
Article Synopsis
- The study tested the pharmacokinetic (PK) equivalence of the adalimumab biosimilar CT-P17 compared to both US-licensed and EU-approved adalimumab through a clinical trial with healthy participants.
- Participants were randomly assigned to receive either CT-P17, US-adalimumab, or EU-adalimumab, and the study measured key PK indicators like concentration-time curves and maximum serum concentration.
- Results showed that CT-P17 was pharmacokinetically equivalent to the other adalimumab versions, with similar safety and immunogenicity profiles, supporting its potential as a viable biosimilar option.
